Skip to main content


Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

Fig. 4

The effects of dapagliflozin on circulating markers of inflammation. a Monocyte chemoattractant protein-1 (MCP-1); b interleukin-1 beta (IL-1β); c interleukin-6 (IL-6); d interleukin-17 (IL-17); e interleukin-10 (IL-10); f chemokine ligand 5 (CCL5). Data are expressed as mean ± SEM; *p < 0.05 vs all other groups; $p < 0.05 vs Con and Db + dapa; n = 3–8/group. ND below detectable limits

Back to article page